Dividends and BioNTech looking to develop mRNA based malaria vaccine

During the pandemic as governments close down people gathering, there was little good news for the average person. Companies and people adapted to find tools to work from home as seamlessly as if they were in an office and that benefited a portion of the population. The other part managed with increased employment benefits, however there is good news coming from the COVID pandemic.

In an article by Frank Jordans of the Associated Press, a pharmaceutical company, BioNTech said it will use the mRNA technology to target malaria. The good news is because all the big pharma companies has been working together on the COVID vaccines, the technology allowed for a few years advancement in results.

According to the World Health Organization, there were 229 million cases of malaria in 2019. About 400,000 died with children under 5 accounting for 67% of the deaths.

BioNTech CEO Ugur Sahin said we are working on HIV, TB and malaria – all with a high unmet medical need. The company noted the knowledge and technology learned from the COVID vaccine will help make strides in these other diseases.

Linking to dividend paying stocks, with every downturn we always hope people learn something to help protect from the next downturn. In the medical world, there is great hope from what has been learnt and using artificial intelligence to learn even more. If and when new drugs come out, one would expect the price to be used to combat the disease will both be reasonable and profitable for big pharma companies.

There are more questions than answers, till the next time – to raising questions.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s